Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks 6 psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them), and have market capitalizations in excess of $50M.

Below are the performances of the 6 constituents for this week, in descending order, and for the past 4 weeks and the extent to which each company is likely to encounter financial stress and/or bankruptcy in the next 2 years compared to its peers according to their Altman Z-Scores (as sourced from macroaxis.com).

1. GH Research (GHRS): UP 12.0% this week; UP 11.8% in the last 4 weeks
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
   • has a 77% chance of encountering financial stress in the next 2 years.
2. Mind Medicine (MNMD): UP 2.6% this week; DOWN 7.9% in the last 4 weeks
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
   • has a +73% chance of encountering financial stress in the next 2 years.
3. Compass Pathways (CMPS): UP 0.9% this week; DOWN 8.6% in the last 4 weeks
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
   • has a 28% chance of encountering financial stress in the next 2 years.
4. Atai (ATAI): UP 0.7% this week; UP 3.0% in the last 4 weeks
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
   • has a 53% chance of encountering financial stress in the next 2 years
5.  Seelos (SEEL): No Change this week; DOWN 6.8% in the last 4 weeks
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
   • has a 56% chance of encountering financial stress in the next 2 years.
6.  Cybin (CYBN): DOWN 2.3% this week; DOWN 8.5% in the last 4 weeks
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
   • has a 77% chance of encountering financial stress in the next 2 years.

In addition, it should be noted that (source) NONE of the above companies:

• • has a positive net operating cash flow
  • has a positive earnings before interest, taxes, depreciation or amortization (EBITDA) or
  • has shown any improvement in either of the above metrics in the past quarter.

In summary, the above 6 stocks went UP 5.2%, on average, last week and UP 0.2% over the past 4 weeks. YTD, the Index is DOWN 52.3%.

Six (6) other psychedelic companies are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, and substance abuse withdrawal, and depression. They are identified below with a description of each of their commercialization developments:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
   • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
     • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
     • is developing MDMA-assisted therapy for AUM
   •  Is also in the process of developing KAT for Gambling Disorder
   • Go here for the company's latest quarterly (Q2) financial results
2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
   • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF)
   • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems
   • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
   • has 3 KAT clinics in Canada;
   • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program
   • Has 6 KAT clinics in Utah and 2 in Arizona
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF)
   • Has 10 KAT clinics in 6 states and 9 options on other clinics
6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
   • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the U.S.) facilitating research and development toward medicalization

The above 6 psychedelic-assisted therapy clinic stocks went DOWN 1.5%, on average, last week unchanged from the end of October (4 weeks).

More By This Author:

British American Tobacco Company Buys Into An American MSO Cannabis
Cannabis Category Performances Ranged From +2.6% To -5.8% Last Week
American MSO Stocks Index Up Considerably - Is The Bottom Finally In?